Report Phase 1 hepatic impairment clinical trial results
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 22 Jan 2024
- Due
- 31 Mar 2024
- Delivered
- 27 Mar 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 1 hepatic impairment results 1Q 2024”
What we found
Evidence strength B What the grades mean
Sagimet announced completion of Phase 1 hepatic impairment study on March 27, 2024, within the Q1 2024 deadline.
-
B Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study Company investor relations confirmation of Phase 1 hepatic impairment study completion
-
B Pipeline - Sagimet Biosciences Current company pipeline page states Phase 1 hepatic impairment results reported 1Q 2024
-
D Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat Official announcement of Phase 1 hepatic impairment study completion on March 27, 2024
Checked 21 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Sagimet Biosciences Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-SGMT-000047 · Corrections policy